Associated Papers
Natural History of Germline BRCA1 Mutated and BRCA Wild-type Triple-negative Breast Cancer.
Gardi N et al.
Cancer Research Communications, 2024
38315150 (PubMed )
Supplement: crc-23-0277-s13.xlsx › Sheet1
Genetic variants of genes involved in thiopurine metabolism pathway are associated with 6-mercaptopurine toxicity in pediatric acute lymphoblastic leukemia patients from Ethiopia.
Ali AM et al.
Frontiers in Pharmacology, 2023
Individualized Proteogenomics Reveals the Mutational Landscape of Melanoma Patients in Response to Immunotherapy.
Schmitt M et al.
Cancers, 2021
34771574 (PubMed )
Supplement: cancers-13-05411-s001.zip › cancers-1421686_Table_S4.xlsx › Sheet_1
Thiopurine-induced toxicity is associated with dysfunction variant of the human molybdenum cofactor sulfurase gene (xanthinuria type II).
Stiburkova B et al.
Toxicology and Applied Pharmacology, 2018
Treatment-associated TP53 DNA-binding domain missense mutations in the pathogenesis of secondary gliosarcoma.
Pain M et al.
Oncotarget, 2018
29416795 (PubMed )
Supplement: oncotarget-09-2603-s001.pdf
Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose.
Carroll MB et al.
Rheumatology International, 2017
Genes implicated in thiopurine-induced toxicity: Comparing TPMT enzyme activity with clinical phenotype and exome data in a paediatric IBD cohort.
Coelho T et al.
Scientific Reports, 2016
Polymorphism of genes involved in purine metabolism (XDH, AOX1, MOCOS) in kidney transplant recipients receiving azathioprine.
Kurzawski M et al.
Therapeutic Drug Monitoring, 2012
Identification and characterization of the first mutation (Arg776Cys) in the C-terminal domain of the Human Molybdenum Cofactor Sulfurase (HMCS) associated with type II classical xanthinuria.
Peretz H et al.
Molecular Genetics and Metabolism, 2007
Select a paper to view details